Quang X. Pham

interim Chief Financial Officer and interim Principal Accounting Officer, Cadrenal Therapeutics, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Cadrenal Therapeutics, Inc. named John P. Sharp to succeed Quang X. Pham on an interim basis, effective June 25, 2026.² Cadrenal Therapeutics, Inc. named Quang X. Pham interim Chief Financial Officer and interim Principal Accounting Officer, effective May 28, 2026.¹

The filing gives Quang X. Pham's previous role as Chief Executive Officer at Cadrenal Therapeutics, Inc.¹ Quang X. Pham already worked at Cadrenal Therapeutics, Inc. when appointed, so the record counts the move as an internal promotion.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Cadrenal Therapeutics, Inc. (CVKD) Pharmaceutical Preparations	interim Chief Financial Officer and interim Principal Accounting Officer	Former	2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

June 25, 2026effective
Cadrenal Therapeutics, Inc. named John P. Sharp to succeed Quang X. Pham on an interim basis, effective June 25, 2026. Profile of John P. Sharp.
Pham ceased to serve as the Company’s Interim Chief Financial Officer.
[2] Filing by Cadrenal Therapeutics, Inc., filed with the SEC on June 29, 2026. Read the filing. The record at CFO Tribune.
May 28, 2026effective
Cadrenal Therapeutics, Inc. named Quang X. Pham interim Chief Financial Officer and interim Principal Accounting Officer, effective May 28, 2026. Profile of Matthew K. Szot.
Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.
[1] Filing by Cadrenal Therapeutics, Inc., filed with the SEC on June 3, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Cadrenal Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 3, 2026. sec.gov; record.
Current report filed with the SEC, Cadrenal Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 29, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Quang X. Pham wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.